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1123-179 Comparison Between Rescue Surgical Embolectomy 
and Repeat Thrombolysis After Unsuccessful 
Thrombolysis in Acute Pulmonary Embolism
Nicolas Meneveau, Luc Lorgis, Pierre Legalery, Marie-France Seronde, Florent Briand, 
Francois Schiele, Yvette Bernard, Jean-Pierre Bassand, University Hospital Jean Minjoz, 
Besancon, France
Background: Persistence of pulmonary hypertension (PH) or right ventricular(RV) dys-
function after thrombolytic therapy (TT) in acute pulmonary embolism (APE) is associ-
ated with increased long-term mortality. However, management of unsuccessful TT has
never been assessed in this setting. The aim of this study was to compare rescue surgi-
cal embolectomy and repeat thrombolysis in APE pts presenting with persistent RV dys-
function and haemodynamic instability after TT.
Methods: 354 consecutive APE pts submitted to TT were prospectively included in a
monocenter registry. 37(10%) had persistent haemodynamic instability (heart rate
>100bpm, systolic blood pressure <90mmHg or refractory cardiogenic shock) and resid-
ual RV dysfunction at 48h echocardiography (paradoxical septal motion, pulmonary
hypertension >40 mmHg or RV/LV end diastolic diameter >1). The choice between res-
cue surgical embolectomy and repeat thrombolysis was left to the physician in charge. In-
hospital course was assessed using a clinical composite endpoint defined as recurrent
PE, bleeding complications or PE-related death.
Results: Clinical presentation and echocardiographic examination were similar in both
groups before and after TT. In-hospital events are summarized in the table.
Conclusion: Rescue surgical embolectomy led to better in-hospital course when com-
pared with repeat thrombolysis in pts with persistent RV dysfunction and haemodynamic
instability after TT. A randomized trial is needed in this area.
1123-180 Incidence and Evaluation of Heparin-Induced 
Thrombocytopenia (HIT) Among Patients Treated With 
Prolonged Heparin and Among Thrombocytopenic 
Patients in the Cardiac Care Unit: Preliminary Results of 
the CATCH Registry
Eric M. Crespo, Richard C. Becker, Peter B. Berger, Christopher B. Granger, Neal S. 
Kleinman, David J. Moliterno, Stephan Moll, Lawrence Rice, Charles S. Abrams, JoEllen 
Rogers, Stephen S. Steinhubl, Victor F. Tapson, Kevin J. Anstrom, E. Magnus Ohman, 
School of Medicine, University of North Carolina at Chapel Hill, Chapel, NC, University of 
Massachusetts Medical Center, Worcester, MA
Background: Heparin-induced thrombocytopenia (HIT) occurs in an estimated 1-5% of
patients receiving heparin. Given that approximately 5 million cardiovascular patients in
the United States receive heparin each year, HIT represents a substantial public health
concern. The complications of HIT are well known, but the true incidence of HIT and the
best approach to treating it are not. Methods: In building the CATCH (Complications
After Thrombocytopenia Caused by Heparin) Registry, we aim to clarify the incidence,
evaluation, and outcomes of HIT by enrolling more than 7,000 patients who either have
received >96 hours of heparin or low-molecular-weight heparin (LMWH) or who develop
thrombocytopenia (platelet count <150,000 or >50% drop from admission value) while in
the CCU. Real-time data are being collected at >50 US hospitals. Results: Data from
March to September 2003 are currently available. Of 1,020 patients who received hep-
arin for >96 hours (36% had a cardiac cause as the primary reason for admission), the
most common reasons for heparin treatment were venous thrombosis prophylaxis
(67.4%), treatment for acute coronary syndrome (13.5%), or atrial fibrillation (7.3%). Of
164 patients who developed thrombocytopenia in the CCU, 94.4% were on either heparin
or LMWH. Conclusion: Initial CATCH data demonstrate that thrombocytopenia is com-
mon among patients treated with prolonged heparin, but that recognition, serologic test-
ing, and hematology consult are uncommon and delayed. 
1123-181 Thromboprophylaxis With Dalteparin Reduces Clinically 
Important Venous Thromboembolism in Patients With 
Congestive Heart Failure
Alexander G. Turpie, Alexander T. Cohen, Carl-Gustav Olsson, Paul T. Vaitkus, Samuel 
Z. Goldhaber, Alain Leizorovicz, The PREVENT Medical Thromboprophylaxis Study 
Group, Hamilton Health Sciences, Hamilton, ON, Canada
Background: Patients with congestive heart failure are at risk of venous thromboembo-
lism (VTE). However, the benefit of pharmacological thromboprophylaxis in patients with
congestive heart failure has not been well studied and hence is not universally accepted
or adopted. We undertook a subanalysis of the recently completed Prospective Evalua-
tion of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients Trial (PRE-
VENT), which evaluated dalteparin for prevention of clinically important VTE in acutely ill
medical patients, to assess the benefit of thromboprophylaxis in patients admitted with
congestive heart failure.
Methods: PREVENT was a randomized, double-blind, placebo-controlled trial in 219 cen-
ters in 26 countries, which enroled hospitalized medical patients at moderately high risk
of VTE. In total, 3,706 patients were included in the study, among whom 1,595 were
admitted with congestive heart failure (NYHA class III or IV). Patients received dalteparin
(5,000 IU QD) or placebo for 14 days. The primary endpoint was clinically important VTE,
defined as objectively verified symptomatic deep vein thrombosis, pulmonary embolism,
sudden death, and objectively verified asymptomatic proximal deep vein thrombosis.
Compression ultrasound was performed in all patients who had not reached an endpoint
by day 21.
Results: Overall, the incidence of the composite primary outcome was 2.77% in the
dalteparin group and 4.96% in the placebo group, a risk reduction of 45% (95% CI: 20%-
62%) (p=0.0015). Major bleeding was reported in 9 (0.49%) patients receiving dalteparin
and 3 (0.16%) receiving placebo (n.s.). Among the patients admitted with congestive
heart failure, the primary endpoint incidence was 3.07% (25/814) in the dalteparin group
and 4.23% (33/781) in the placebo group, a risk reduction of 27% (95% CI: -21% to
56%).
Conclusion: Dalteparin in a fixed dose of 5,000 IU daily reduces the rate of clinically
important VTE in acutely ill medical patients, including those with congestive heart fail-
ure, with a low risk of bleeding.
1123-182 Obesity Does Not Attenuate the Effectiveness of Low-
Dose Dalteparin in Preventing Venous 
Thromboembolism in Medically Ill Patients
Nils Kucher, Alain Leizorovicz, Alexander T. Cohen, Alexander G. Turpie, Carl-Gustav 
Olsson, Paul T. Vaitkus, Samuel Z. Goldhaber, The PREVENT Medical 
Thromboprophylaxis Study Group, Brigham and Women's Hospital, Boston, MA
Background: Dalteparin, a low-molecular-weight heparin, is used in fixed, low doses to
prevent venous thromboembolism (VTE). We were concerned that a fixed rather than
weight-based dosing regimen of LMWH might result in decreased efficacy in obese med-
ically ill patients.
Methods: We analyzed data from the PREVENT trial, a study of 3,706 hospitalized, med-
ically ill patients at least 40 years of age, with a projected hospitalization of 4 or more
days, who had been randomized to receive either dalteparin 5,000 units once daily or
placebo. The primary endpoint of the trial was a composite of symptomatic VTE, fatal pul-
monary embolism (PE), sudden death, or asymptomatic proximal deep venous thrombo-
sis by day 21 in the intention-to-treat population. Obesity, defined as a body mass index
greater than or equal to 30 kg/m2 for men and greater than or equal to 28.6 kg/m2 for
women, was present in 1,118 (30.2%) patients.
Results: In obese patients, the primary endpoint occurred in 2.8% and 4.3% of the dalte-
parin and placebo group, respectively (RR 0.64; 95% CI: 0.32-1.28). In non-obese
patients, the primary endpoint was reported in 2.8% and 5.2% of the dalteparin and pla-
cebo group, respectively (RR 0.53; 95% CI: 0.34-0.82). The incidence of fatal PE or sud-
den death by day 21 was similar in obese (dalteparin: 0.4%; placebo: 0.4%) and non-
obese patients (dalteparin: 0.2%; placebo: 0.1%). With multivariate logistic regression,
the treatment effect of dalteparin remained unchanged (OR 0.55; 95% CI: 0.37-0.80)
when adjusted for obesity and older age >75 years. Data modeling using the variables of
obesity, dalteparin, and interaction term indicated that the efficacy of dalteparin was not
significantly altered in obese patients (p=0.63). When weight was modeled as a continu-
ous variable, no statistically significant interaction between dalteparin and obesity was
observed (p=0.97).
Conclusion: A fixed low dose of dalteparin of 5,000 units once daily reduces the risk of
VTE to a similar extent in obese and non-obese medically ill patients. These results
should encourage more widespread use of fixed, low-dose dalteparin to prevent VTE in
hospitalized medical patients who are obese.
1123-183 Sustained Hemodynamic Benefit in Patients With 
Pulmonary Arterial Hypertension After One-Year of 
Therapy With the Selective Orally-Active Endothelin-A 
Receptor Antagonist, Sitaxsentan
David Langleben, Andrew Hirsch, Eileen Shalit, Lyda Lesenko, Robyn J. Barst, Sir 
Mortimer B Davis Jewish General Hospital, Montreal, PQ, Canada, Columbia University, 
New York, NY
Background: The natural history of pulmonary arterial hypertension (PAH) is one of pro-
gressive deterioration leading to death. Endothelin-1 (ET), a potent vasoconstrictor and
mitogenic peptide, has been implicated in the pathogenesis of PAH, and blockade of its
effects has become a therapeutic focus. We report long-term hemodynamic improvement
in patients with PAH who were treated with the orally active selective ETA receptor antag-
onist, sitaxsentan sodium.
Methods: In a Compassionate Use protocol, 11 patients with PAH (4 idiopathic, 3 con-
Surgical embolectomy 
(n=12)
Repeat thrombolysis 
(n=25)
p
Recurrent PE 3 (25%) 15 (60%) <10-5
Bleedings 2 (17%) 6 (24%) 0.53
PE-related death 0 (0%) 6 (24%) 0.002
1 or more of the above 4 (33%) 20 (80%) <10-5
Heparin >96 
Hours
(n=1,020)
Thrombocytopenia in 
CCU
(n=164)
Thrombocytopenia 29.4% 100%
Days after admission (mean) 2.3 1.8
Serologic test for HIT performed 1.9% 16.7%
Days after admission (mean) 4.8 5.8
Hematology consult 3.3% 2.9%
Days after admission (mean) 7.7 18.3
Recovery of platelet count 37% 64.8%
Days after admission (mean) 6.8 6.8
Discharge diagnosis of
thrombocytopenia
2.5% 12.6%
Final Diagnosis of HIT (positive 
serology)
0.2% 2.1%
